Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.

Paz-Ares, Luis; Soulières, Denis; Moecks, Joachim; Bara, Ilze; Mok, Tony; Klughammer, Barbara

Paz-Ares, Luis; Soulières, Denis; Moecks, Joachim; Bara, Ilze; Mok, Tony; Klughammer, Barbara.

Affiliation

Paz-Ares L; Department of Medical Oncology, Instituto de Biomedicina de Sevilla (HUVR, US and CSIC) and Hospital Universitario Virgen del Rocio, Seville, Spain.

J Cell Mol Med ; 18(8): 1519-39, 2014 Aug.

Article in En | MEDLINE | ID: mdl-25100284

Subject(s)

Carcinoma, Non-Small-Cell Lung/drug therapy; ErbB Receptors/genetics; Lung Neoplasms/drug therapy; Mutation/genetics; Protein Kinase Inhibitors/therapeutic use; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/mortality; Humans; Lung Neoplasms/genetics; Lung Neoplasms/mortality; Meta-Analysis as Topic; Prognosis; Review Literature as Topic; Survival Rate

Key words

afatinib; epidermal growth factor receptor (EGFR); erlotinib; first line; gefitinib; icotinib; mutation; non-small-cell lung cancer (NSCLC); tyrosine-kinase inhibitor

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / ErbB Receptors / Lung Neoplasms / Mutation Type of study: Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2014 Document type: Article Affiliation country: Spain Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google